139 related articles for article (PubMed ID: 36600109)
21. Classification, Prediction, and Concordance of Cognitive and Functional Progression in Patients with Mild Cognitive Impairment in the United States: A Latent Class Analysis.
Mouchet J; Betts KA; Georgieva MV; Ionescu-Ittu R; Butler LM; Teitsma X; Delmar P; Kulalert T; Zhu J; Lema N; Desai U
J Alzheimers Dis; 2021; 82(4):1667-1682. PubMed ID: 34219723
[TBL] [Abstract][Full Text] [Related]
22. Longitudinal Sensitivity of Alzheimer's Disease Severity Staging.
Benoit JS; Chan W; Piller L; Doody R
Am J Alzheimers Dis Other Demen; 2020; 35():1533317520918719. PubMed ID: 32573256
[TBL] [Abstract][Full Text] [Related]
23. Progression of Alzheimer's disease as measured by Clinical Dementia Rating Sum of Boxes scores.
Williams MM; Storandt M; Roe CM; Morris JC
Alzheimers Dement; 2013 Feb; 9(1 Suppl):S39-44. PubMed ID: 22858530
[TBL] [Abstract][Full Text] [Related]
24. Is Ongoing Anticholinergic Burden Associated With Greater Cognitive Decline and Dementia Severity in Mild to Moderate Alzheimer's Disease?
Dyer AH; Murphy C; Segurado R; Lawlor B; Kennelly SP;
J Gerontol A Biol Sci Med Sci; 2020 Apr; 75(5):987-994. PubMed ID: 31613323
[TBL] [Abstract][Full Text] [Related]
25. Predicting the time to clinically worsening in mild cognitive impairment patients and its utility in clinical trial design by modeling a longitudinal clinical dementia rating sum of boxes from the ADNI database.
Ito K; Hutmacher MM
J Alzheimers Dis; 2014; 40(4):967-79. PubMed ID: 24531162
[TBL] [Abstract][Full Text] [Related]
26. Distinct dynamic profiles of microglial activation are associated with progression of Alzheimer's disease.
Hamelin L; Lagarde J; Dorothée G; Potier MC; Corlier F; Kuhnast B; Caillé F; Dubois B; Fillon L; Chupin M; Bottlaender M; Sarazin M
Brain; 2018 Jun; 141(6):1855-1870. PubMed ID: 29608645
[TBL] [Abstract][Full Text] [Related]
27. The antibody aducanumab reduces Aβ plaques in Alzheimer's disease.
Sevigny J; Chiao P; Bussière T; Weinreb PH; Williams L; Maier M; Dunstan R; Salloway S; Chen T; Ling Y; O'Gorman J; Qian F; Arastu M; Li M; Chollate S; Brennan MS; Quintero-Monzon O; Scannevin RH; Arnold HM; Engber T; Rhodes K; Ferrero J; Hang Y; Mikulskis A; Grimm J; Hock C; Nitsch RM; Sandrock A
Nature; 2016 Sep; 537(7618):50-6. PubMed ID: 27582220
[TBL] [Abstract][Full Text] [Related]
28. Comparing measures of decline to dementia in amnestic MCI subjects in the National Alzheimer's Coordinating Center (NACC) Uniform Data Set.
Monsell SE; Liu D; Weintraub S; Kukull WA
Int Psychogeriatr; 2012 Oct; 24(10):1553-60. PubMed ID: 22717299
[TBL] [Abstract][Full Text] [Related]
29. Amyloid-Related Imaging Abnormalities in 2 Phase 3 Studies Evaluating Aducanumab in Patients With Early Alzheimer Disease.
Salloway S; Chalkias S; Barkhof F; Burkett P; Barakos J; Purcell D; Suhy J; Forrestal F; Tian Y; Umans K; Wang G; Singhal P; Budd Haeberlein S; Smirnakis K
JAMA Neurol; 2022 Jan; 79(1):13-21. PubMed ID: 34807243
[TBL] [Abstract][Full Text] [Related]
30. Cohort Effects in Progression Rate on Cognitive and Functional Measures in an Alzheimer's Disease Clinical Cohort.
Pavlik VN; Chan W; Darby E
J Alzheimers Dis; 2019; 71(2):659-669. PubMed ID: 31424408
[TBL] [Abstract][Full Text] [Related]
31. Application of Meta-analysis to Evaluate Relationships Among ARIA-E Rate, Amyloid Reduction Rate, and Clinical Cognitive Response in Amyloid Therapeutic Clinical Trials for Early Alzheimer's Disease.
Wang D; Kowalewski EK; Koch G
Ther Innov Regul Sci; 2022 May; 56(3):501-516. PubMed ID: 35320578
[TBL] [Abstract][Full Text] [Related]
32. Suitability of the Clinical Dementia Rating-Sum of Boxes as a single primary endpoint for Alzheimer's disease trials.
Coley N; Andrieu S; Jaros M; Weiner M; Cedarbaum J; Vellas B
Alzheimers Dement; 2011 Nov; 7(6):602-610.e2. PubMed ID: 21745761
[TBL] [Abstract][Full Text] [Related]
33. Correction to: Characterization of exposure-Clinical Dementia Rating-Sum of Boxes relationship in subjects with early Alzheimer's disease from the aducanumab Phase 3 trials.
Muralidharan KK; Kowalski KG; Tong X; Haeberlein SB; Rajagovindan R; Nestoro I
J Pharmacokinet Pharmacodyn; 2023 Apr; 50(2):145. PubMed ID: 36870006
[No Abstract] [Full Text] [Related]
34. Progression of Alzheimer's disease during a three-year follow-up using the CERAD-NB total score: Kuopio ALSOVA study.
Hallikainen I; Hänninen T; Fraunberg M; Hongisto K; Välimäki T; Hiltunen A; Karppi P; Sivenius J; Soininen H; Koivisto AM;
Int Psychogeriatr; 2013 Aug; 25(8):1335-44. PubMed ID: 23676340
[TBL] [Abstract][Full Text] [Related]
35. A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer's disease in the nursing home setting.
Tariot PN; Cummings JL; Katz IR; Mintzer J; Perdomo CA; Schwam EM; Whalen E
J Am Geriatr Soc; 2001 Dec; 49(12):1590-9. PubMed ID: 11843990
[TBL] [Abstract][Full Text] [Related]
36. Metrological properties of neuropsychological tests for measuring cognitive change in individuals with prodromal Alzheimer's disease.
Zhang X; Wu Y; He Y; Ge X; Cui J; Han H; Luo Y; Liu L; Wang Z; Yu H;
Aging Ment Health; 2022 Oct; 26(10):1988-1996. PubMed ID: 34409904
[TBL] [Abstract][Full Text] [Related]
37. The need to show minimum clinically important differences in Alzheimer's disease trials.
Liu KY; Schneider LS; Howard R
Lancet Psychiatry; 2021 Nov; 8(11):1013-1016. PubMed ID: 34087114
[TBL] [Abstract][Full Text] [Related]
38. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
39. Sum of boxes of the clinical dementia rating scale highly predicts conversion or reversion in predementia stages.
Tzeng RC; Yang YW; Hsu KC; Chang HT; Chiu PY
Front Aging Neurosci; 2022; 14():1021792. PubMed ID: 36212036
[TBL] [Abstract][Full Text] [Related]
40. Progression of Alzheimer's Disease: A Longitudinal Study in Norwegian Memory Clinics.
Eldholm RS; Barca ML; Persson K; Knapskog AB; Kersten H; Engedal K; Selbæk G; Brækhus A; Skovlund E; Saltvedt I
J Alzheimers Dis; 2018; 61(3):1221-1232. PubMed ID: 29254085
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
